Strides Pharma Science Partners with Ascent Capital in Strategic Investment of Pivot Path

Strides Pharma Science Partners with Ascent Capital in Strategic Investment of Pivot Path​

Bangalore, India, June 27, 2026 — Strides Pharma Science Limited today announced a strategic investment by a consortium led by Ascent Capital, alongside coinvestor Vintage Classic, into its subsidiary, Pivot Path Private Limited. The transaction aims to unlock value and accelerate the growth trajectory of the specialized business unit.

The deal values Pivot Path at approximately ₹2,300 million on a post-money basis. This investment enables Strides to realize around ₹1,000 million while retaining roughly 20% ownership stake in the company. Furthermore, the transaction includes a primary capital infusion of ₹500 million provided by the investors to support Pivot Path's next phase of growth and expansion strategy.

The strategic move reflects Strides’ approach of creating, scaling, and unlocking value from high potential businesses while maintaining meaningful participation in their future development. The investment is set to strengthen the Company’s balance sheet and provide essential growth capital for Pivot Path.

Pivot Path originated within Arco Lab Private Limited, which functioned as part of Strides' Global Capability Centre (GCC). It developed core capabilities across life sciences consulting, quality and compliance, digital transformation, and technology enabled operational services. As demand from external pharmaceutical and life sciences companies increased, the business evolved into an independent platform serving industry leading customers.

Following its incorporation into Pivot Path, which was carved out through a Scheme of Arrangement approved in May 2026, the company is set to be reclassified as an Associate of Strides upon transaction completion. The transaction was based on an independent valuation conducted by a SEBI registered merchant banker and reflects the established customer relationships and differentiated capabilities of Pivot Path.

Operational Strength and Financials​

Pivot Path operates as a profitable platform serving specialized, high-value segments within the life sciences industry, focusing on delivering domain driven solutions supported by advanced technologies, including AI and analytics.

For Fiscal Year 2026, the carved out business reported significant operational metrics:


Badree Komandur, MD and Group CEO of Strides, commented on the transaction. "Pivot Path exemplifies Strides' proven capability to identify, incubate and scale high potential businesses," he stated. "As the business enters its next phase, we believe this is the right time to bring in a strategic investment partner with the expertise and capital to accelerate its growth. This transaction unlocks value for Strides, provides Pivot Path with the resources to scale independently, and allows Strides to retain meaningful participation in its future success."

Raja Kumar, Managing Director and Founder of Ascent Capital, added that Pivot Path holds deep domain expertise across core, non discretionary segments of the pharmaceutical industry. "As an Independent entity, Pivot Path is exceptionally well positioned to combine the power of technology and Agentic-AI with its 400+ subject matter experts in building purpose built solutions," he commented.

About Pivot Path and Ascent Capital​

Pivot Path Private Limited is a technology enabled life sciences and manufacturing solutions company that provides domain driven services through consulting, digital innovation, and operational support. It focuses on addressing complex challenges in the pharmaceutical and manufacturing sectors using advanced technologies like AI and analytics.

Ascent Capital Advisors India Pvt Ltd is an India focused private equity firm with over 175 years of collective experience. The firm partners with high growth companies across technology and healthcare, employing an entrepreneur centric investment approach to provide strategic and operational support for sustainable scaling.

Strides, a global pharmaceutical company based in Bengaluru, operates in regulated markets and has an 'in Africa for Africa' strategy. Its global manufacturing sites are located in India, Italy, Kenya, and the United States, focusing on difficult to manufacture products sold in over 100 countries.

STAR Stock Price Movement​

Shares of Strides Pharma Science Limited slipped by 3.26% on Thursday, closing at ₹1082.2 after shedding ₹36.20 from the previous close. The stock saw a traded volume of 183,992 shares, with the price trading near the day's low of ₹1072.